leisure time -WSS

leisure time

author：entertainment 2025-09-29 21:14:38 - browse：17214

Vivistim and Lead — A small Texas company is testing whether pairing vagus nerve stimulation with rehabilitation exercise can restore movement in people who have had a stroke. STAT/MicroTransponder, Inc.

Despite being forced by Hurricane Irma to close its outpatient facilities for several days, the Mayo Clinic in Jacksonville, Fla., is expected to forge ahead this month with a pivotal clinical trial testing whether an electrical implant can rewire the brains of stroke patients so they can use their arms and hands again.

If the patients who receive implants regain significantly more function than those who get only standard rehabilitation, it will show that stroke-damaged brain circuits can be bypassed like shorts in a circuit board, with healthy neurons coaxed into performing the job of those fried by stroke.

Although the results might not be make-or-break for the little 11-year-old Texas company sponsoring the trial (called MicroTransponder, the company’s also testing whether an electrical implant can alleviate tinnitus), there will be more evidence of whether “electroceuticals” — electrical stimuli tailored to treat diseases — work beyond their current use in controlling pain and a few other conditions or will fall short of the buzz surrounding them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Streamlined flu vaccines recommended by FDA advisory panel

WSS

First over

The public health thinking behind the CDC’s new Covid guidance

U.K. researchers warn about biases in medical devices, algorithms

Fetal cell organoids grown from amniotic fluid, study finds

5 to watch: Tech startups trying to solve health care's staffing crisis

Orchard's therapy for neuron disease in children wins FDA approval

knowledge

leisure time

focus

Wildfire smoke exposes gaps in outdoor worker protections

First over

Trump demands the U.S. pay no more for drugs than other countries … again

He's 19 months old and has one of the world’s rarest diseases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

$1 billion proposal to grow Boston, Massachusetts biotech

In age of alternative facts, a scholarly course on calling out crap

Methadone treatment changes are coming. Do they go far enough?

Heart attack and stroke risk calculators need revising

Asbestos, a deadly carcinogen, banned by EPA

focus

Harvard's David Sinclair gets blowback over aging

Virtual Event: March of the Biosimilars

Creating egg and sperm cells from stem cells raises ethical issues

5 to watch: Tech startups trying to solve health care's staffing crisis

Microsoft's Peter Lee: Generative AI could help doctors be more human

Orchard's therapy for neuron disease in children wins FDA approval

knowledge

hotspot

entertainment

leisure time